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Abstract
Background: Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this
gender disparity are still poorly understood. In this respect, calcitonin gene-related peptide (CGRP) plays a key role in
migraine pathophysiology and, more recently, the functional interactions between ovarian steroid hormones, CGRP and
the trigeminovascular system have been recognized and studied in more detail.
Aims: To provide an overview of CGRP studies that have addressed gender differences utilizing animal and human
migraine preclinical research models to highlight how the female trigeminovascular system responds differently in the
presence of varying ovarian steroid hormones.
Conclusions: Gender differences are evident in migraine. Several studies indicate that fluctuations of ovarian steroid
hormone (mainly estrogen) levels modulate CGRP in the trigeminovascular system during different reproductive mile-
stones. Such interactions need to be considered when conducting future animal and human experiments, since these
differences may contribute to the development of gender-specific therapies.
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Introduction
Migraine is a complex neurovascular disorder associated
with dysfunction of the nociceptive trigeminovascular
system (1). Migraine is two to three times more prevalent
in women than in men (2). Additionally, women have
more frequent and intense headaches, a higher risk of
chroniﬁcation, greater disability and an increased risk of
cardiovascular events, including cardiovascular mortal-
ity (2,3). Although the precise mechanisms underlying
this unique gender-dependent prevalence are not fully
understood, they seem to be related to the hormonal
ﬂuctuations of ovarian steroid hormones, namely estro-
gens and progesterone.
Migraine prevalence before puberty is similar
between sexes. A notably increased incidence arises in
women after menarche, where hormonal ﬂuctuations
inﬂuence migraine occurrence during diﬀerent repro-
ductive milestones, such as menstruation, pregnancy,
the postpartum state and breastfeeding, perimenopause
and menopause (4–6). Furthermore, migraine fre-
quency is aﬀected by the use of oral contraceptive
pills, hormone replacement therapy, selective estrogen
receptor modulators (i.e. tamoxifen) and medical
oophorectomy (7–9). Interestingly, rates of migraine
similar to those in females were reported in male-to-
female transsexuals under estrogen therapy to induce
female sex characteristics (10). This relationship
between ﬂuctuations of ovarian steroid hormones and
migraine incidence was suggested almost half a century
ago by Somerville (11). He stated that in biologically-
predisposed women, migraine attacks are triggered by
a decline in plasma estrogen concentrations in the late
luteal (premenstrual) phase of the menstrual cycle
(4,11). On the contrary, phases of rising estrogen
levels appear to protect against migraine (12), whereas
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progesterone withdrawal does not seem to precipitate
migraine attacks (13). Additionally, migraine preva-
lence has been associated with menstrual disorders
(e.g. menorrhagia, dysmenorrhea), as well as endomet-
riosis and polycystic ovary syndrome (14–16). Thus,
migraine incidence is inﬂuenced by the (dys)function
of the hypothalamo-pituitary-ovarian system.
In the last years, the calcitonin gene-related
peptide (CGRP) pathway has been discovered to play a
key role in migraine pathophysiology. Revolutionary
experiments revealed that during an acute migraine
attack CGRP is released in signiﬁcant amounts in
the extracerebral circulation (17), that these elevated
levels of CGRP are normalized after triptan treatment
(18), and that infusions of CGRP in migraine patients
provoke migraine attacks (19). In addition, all clinical
trials with anti-CGRP drugs have been positive (20), con-
solidating the evidence for the role of CGRP in migraine.
Therefore, it is important to consider that ﬂuc-
tuations in ovarian steroid hormones levels may inﬂu-
ence CGRP homeostasis. Indeed, the presence of
sex hormone receptors in the trigeminovascular
system suggests that trigeminal neurons are sensitive
to variations in the levels of these hormones (21).
However, the exact functional interactions between
ovarian steroid hormones and CGRP, which could
increase migraine prevalence in women, are not fully
understood.
On this basis, the present review will consider the
current knowledge on the eﬀects of a changing hormo-
nal environment on the modulation of the CGRP sig-
naling pathway in the trigeminovascular system, and
will address some sex-dependent considerations for
future CGRP studies.
CGRP and migraine
CGRP, a neuropeptide with pleiotropic eﬀects,
is involved in diﬀerent biological processes such as
neuromodulation, cardiovascular regulation, inﬂam-
mation, metabolic function, and aging (16). Two homo-
log isoforms have been identiﬁed, namely, a-CGRP and
b-CGRP. a-CGRP is a 37-amino acid neuropeptide
widely distributed throughout the nervous system and
predominantly expressed in sensory Ad- and C-ﬁbers. It
is produced by transcription and alternative RNA spli-
cing of the primary transcript of the calcitonin gene
(23–25). b-CGRP is encoded by a second calcitonin
gene, diﬀering by only a single amino acid in rats and
by three residues in humans (25,26), and predominantly
expressed in the enteric nervous system. Considering
that the majority of studies focus on a-CGRP, this
review will be limited to this isoform, with a focus on
the trigeminovascular system because of its relevance in
migraine.
Migraine pathophysiology has long been related
with activation and sensitization of the trigeminovascu-
lar system, a functional pathway consisting of pseudou-
nipolar neurons peripherally innervating the cranial
vasculature and the dura mater, whose cell bodies are
located in the ipsilateral trigeminal ganglion (27,28),
and centrally projecting axons to the trigeminal nucleus
caudalis and the upper two cervical divisions, known as
the trigeminocervical complex (29). CGRP is highly
expressed throughout the trigeminovascular system
(30), it is synthetized in neuronal cell bodies and
co-stored with tachykinins (especially substance P) in
large granular secretory vesicles (31). During the head-
ache phase of a migraine attack, CGRP is released in
the perivascular space, producing neurogenic vasodila-
tation and nociceptive transmission (17,32).
Diﬀerent experimental migraine models have
focused on the various components of the trigemino-
vascular system. These models indirectly assess periph-
eral nociceptors in the dura mater and cranial arteries
(i.e. neurogenic dilation of pain-sensitive dural blood
vessels) or directly study nociceptive trigeminal ﬁbers.
The next sections will review animal and human experi-
mental studies focusing on CGRP in the trigeminovas-
cular system, where sex-related diﬀerences have been
addressed.
Sex hormone effects in animal
CGRP studies
Migraine is a female-predominant disorder.
Surprisingly, the majority of preclinical studies have
used male animals to limit experimental variations
resulting from natural ﬂuctuations or eﬀects per se of
ovarian steroid hormones (33). A recent study revealed
that in naı¨ve rat medulla and trigeminal ganglion,
there were sex diﬀerences in the mRNA levels of
CGRP and the three components of its receptor,
namely, calcitonin-like receptor (CLR), receptor
activity-modifying protein 1 (RAMP1), and receptor
component protein (RCP, 34), with higher CGRP
levels in the medulla and lower expression of RAMP1,
CLR and RCP-encoding mRNA in female tissues com-
pared to that of males. Even considering that no estrous
cycle staging or hormone measurements were conducted,
this suggests that ﬂuctuating gonadal hormones may
regulate CGRP receptor synthesis, expression, or release
in the trigeminovascular system.
The cranial vasculature and dura mater are well-
documented targets for gonadal steroids, where the
expression of estrogen, progesterone and testosterone
receptors has been previously demonstrated (see
Table 1). These gonadal hormones have diverse and
complex physiological functions in the cranial circula-
tion; besides, there are sex diﬀerences regarding their
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function, such as opposing eﬀects of estrogen and tes-
tosterone on vascular tone (35), but their modulation
on the CGRP system remains largely unknown. A func-
tional study examined the eﬀects of 17b estradiol pre-
treatment on the response to CGRP in isolated basilar
artery segments of female rats. The basilar artery did
not exhibit any variation in the CGRP vascular
responses after chronic estrogen (36). Although the
basilar artery is not primarily involved in migraine
pathophysiology, it was used instead of dural arteries
because the small size of the latter is a limitation for
in vitro studies. In contrast, estrogen ﬂuctuations
during the normal estrous cycle modiﬁed dural mast
cell density, while, in ovariectomized rats, estrogen pre-
treatment promoted an increase in dural mast cell dens-
ity (37), suggesting that gonadal steroids can modify
CGRP function.
Furthermore, androgen and progesterone receptors
are expressed in the diﬀerent components of the trige-
minovascular system (see Table 1). Notwithstanding,
until now, only one study has revealed that the cir-
cadian rhythm of testosterone did not aﬀect CGRP
accumulation in the trigeminal nucleus (38), while in
the lumbar dorsal root ganglion, CGRP was downre-
gulated by long-lasting testosterone treatment (39).
As with the androgen receptors, few studies have
focused on the modulation of CGRP by progesterone.
In this context, the secretion of progesterone seems to
decrease CGRP content in the trigeminal nucleus (38),
while it increased CGRP in the dorsal root ganglion
and in plasma (40). Since studies with these hormones
are very limited, the role of androgen and progesterone
receptors in modulating CGRP in the trigeminovascu-
lar system remains to be determined.
The eﬀects of estrogen have been studied more
widely. There are two classes of estrogen nuclear
receptors, alpha (ERa) and beta (ERb), and a G pro-
tein-coupled estrogen receptor (GPER). All estrogen
receptors are expressed in diﬀerent parts of the trigemi-
novascular system (see Table 1), such as the rodent
trigeminal ganglion (41,42) and dura mater (43).
Although it is believed that estrogens regulate excitabil-
ity and sensitization of the trigeminal CGRP pathway,
experimental data are scarce and inconsistent. In the
female mouse trigeminal ganglion (41) and rat trigem-
inal nucleus (38), CGRP mRNA levels and CGRP con-
tent were constant throughout the phases of the natural
estrous cycle, respectively. In contrast, in the rat trigem-
inal ganglion, ovariectomy signiﬁcantly increased
the gene expression of CGRP compared to cycling
(control) rats, and these increased mRNA levels were
lowered following estrogen replacement (42). Similarly,
in the central nervous system, a deﬁciency of estrogens
increases CGRP levels within the midbrain periaque-
ductal gray (44), medial preoptic nucleus of the hypo-
thalamus (45) and lumbar dorsal root ganglion (46),
while CGRP expression was downregulated after estro-
gen treatment in the dorsal root ganglion (46) and tri-
geminal nucleus caudalis (47). However, it has also
been described that estrogen positively enhances the
expression of CGRP within the dorsal root ganglion
(48–50), rat anterior pituitary (51) and medial preoptic
nucleus (52). Thus, experimental data suggest that
estrogen modulates diﬀerently, and in a complex
manner, the density of CGRP receptors in the periph-
eral and central nervous systems. Further studies are
clearly required to determine the exact role of estro-
gens, and which estrogen receptors are involved,
in the modulation of CGRP expression in the diﬀerent
components of the trigeminovascular system (Figure 1).
The eﬀects of estradiol on the CGRP-ergic system have
also been studied using an epigenetic approach, but the
Table 1. Expression of sex hormone receptors in the different components of the trigeminovascular system. Receptor expression
for animals is only listed when available in the literature.
Cranial blood vessels Dura mater Trigeminal ganglion Trigeminal nerve nuclei
Estrogen rat (82,83) rat (43) mouse (41), rat (42,86) rat (43,86,87)
receptor a human (84) human (85) human ND human (88,89)
Estrogen rat (83) pig (90) rat (86) rat (86)
receptor b human (84) human (85) human ND human (88,89)
GPER rat (91) rat (43) rat (87) rat (43)
human ND human ND human ND human ND
Progesterone rat (93) mouse (94) rat (95)
receptor human (92) human (85) human ND human ND
Androgen rat (82) rat (96) rat (97) rat (98)
receptor human (84) human ND human ND human ND
GPER: G-protein-coupled estrogen receptor 1; ND: not determined in humans.
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variation in the methylation of the CGRP-ergic genes
in that study was too large to allow deﬁnite conclusions
on the role of estradiol (53).
Therefore, an alternative approach to assess the
functional estrogen-CGRP relationship in the whole
trigeminovascular system is with speciﬁc in vivo
animal migraine models. In this context, Gupta et al.
(54) have investigated the modulation exerted by 17b
estradiol and progesterone (separately and in combin-
ation) on dural vasodilation in ovariectomized rats.
Periarterial electrical stimulation of the dural vascula-
ture (i.e. the middle meningeal artery) was applied to
release CGRP from the activated trigeminal nerve. The
subsequent changes in vessel caliber were measured
with intravital microscopy on a closed cranial
window. Dural vasodilation was induced by endogen-
ous (released by periarterial electrical stimulation or
intravenous capsaicin) or exogenous CGRP. The vaso-
dilatory responses to exogenous CGRP or capsaicin
were not aﬀected by ovariectomy or by hormonal
replacement. However, estradiol pretreatment signiﬁ-
cantly enhanced neurogenic sensory vasodilation, sug-
gesting that estrogen modulates prejunctionally the
sensory release of CGRP in trigeminal perivascular
nerve endings in vivo (54).
Another study performed by Martin et al. (55)
explored with an in vivo experimental migraine head-
ache model whether sensitization of the trigeminal
sensory system changes during diﬀerent stages of the
rat estrous cycle. In anesthetized rats, an electrode
was used to record trigeminal nucleus caudalis neurons
activity after cutaneous stimuli and chemical stimula-
tion (with topical capsaicin) of the dura mater. There
was an enhanced sensitization of the trigeminal system
during the later halves of proestrus and estrus, coincid-
ing with an abrupt decline in ovarian steroid hormones
(Figure 2). This ﬁnding suggests that sensitization of
the trigeminal system is dependent on the varying hor-
monal milieus throughout the estrous cycle (55).
In summary, animal studies have provided evidence
that activation of the CGRP system is dependent upon
the diﬀerent stages of the rat estrous cycle, with speciﬁc
roles for the diﬀerent sex hormone receptors. However,
there are hormonal diﬀerences between the rodent
estrous cycle and the human menstrual cycle and, there-
fore, a direct extrapolation to humans should be done
cautiously (55, Figure 2). Evidently, further studies will
be required to delineate the exact mechanism(s)
involved in this (patho)physiological estrogen-CGRP
relationship.
Gender effects in human CGRP studies
One of the ﬁrst clinical studies that discovered a rela-
tionship between female sex hormones and CGRP was
published in 1986 by Stevenson et al. (56). In this study,
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Figure 1. Trigeminovascular system. Sites where estrogens, mainly estradiol (E2), modify CGRP receptor expression/function in
rodents (purple) and humans (blue).
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concentrations of immunoreactive plasma CGRP
(i-CGRP) were measured in healthy controls, through-
out normal pregnancy and in the subacute postpartum
period. i-CGRP concentrations were signiﬁcantly
increased throughout pregnancy, with the highest con-
centrations being found towards term. These increased
in CGRP levels decreased during the ﬁrst days after
delivery, when they were similar to the controls (56),
interestingly, while migraine in many cases seems to be
related to increased CGRP levels, during pregnancy
and around the delivery, an inverse relationship
between CGRP levels and migraine attack incidence
seems to be the case. Most likely, this may be attributed
to diﬀerences between local cranial CGRP levels that
are relevant in migraine, and systemic CGRP levels that
are increased as part of the cardiovascular adaptation
process during pregnancy. Later on, a key study from
Valdemarsson et al. revealed that plasma i-CGRP levels
are diﬀerent between both genders. It is remarkable
that, in healthy subjects, i-CGRP levels were signiﬁ-
cantly higher in females than in males, and that the
use of combined contraceptive pills was associated
with even higher levels of i-CGRP in plasma (57).
Accordingly, in postmenopausal women, decreased
estradiol serum levels were positively correlated
with decreased plasma i-CGRP concentrations (58),
ascribing that the CGRP system could be inﬂuenced
directly by endogenous or exogenous ovarian steroid
hormones.
Is there a gender difference in the func-
tionality of CGRP and the trigemino-
vascular system in humans?
In the last years, some non-invasive human experi-
mental migraine models have relied on laser Doppler
perfusion imaging to study cutaneous antidromic vaso-
dilation induced by chemical stimulation of primary
sensory neurons. In this way, topical application of
capsaicin on the forearm depolarizes nociceptive neu-
rons via activation of prejunctional transient receptor
potential ion channels of the vanilloid type 1 (TRPV1),
leading to release of vasoactive peptides, neurogenic
inﬂammation, and subsequent increase of dermal
blood ﬂow (59). In this pharmacodynamic model, the
capsaicin-induced vasodilation is mediated by release of
CGRP, as this response was inhibited by CGRP recep-
tor antagonists (i.e. CGRP8–37 and telcagepant) and by
a humanized monoclonal antibody directed against
CGRP (60–62).
Using this experimental model, a recent study
explored gender diﬀerences on sensory CGRP release
in healthy subjects and migraine patients, as well as the
inﬂuence of varying levels of estrogen and progesterone
during the menstrual cycle (63). In healthy males,
dermal blood ﬂow responses did not vary over time
and were comparable with the responses of male
migraineurs. However, in healthy women, ﬂuctuations
of ovarian steroid hormones inﬂuenced CGRP-
dependent dermal blood ﬂow, with the highest reactiv-
ity observed around the menstruation period, when
estrogen levels are low. This is in accordance with the
estrogen withdrawal hypothesis, where perimenstrual
low levels of estrogen are associated with a higher
prevalence of migraine (4,11, Figure 2), assuming
that an increased reactivity relates to an increased
vulnerability to a migraine attack. Interestingly, in
female migraine patients, dermal blood ﬂow responses
were elevated compared to healthy subjects, but these
responses were independent of the menstrual cycle.
In this study, serum estradiol and progesterone between
healthy women and migraine patients did not diﬀer
across the hormonal cycle. Therefore, the mechanisms
involved in the increased dermal blood ﬂow in female
migraine patients after capsaicin could be the result of
an increased TRPV1 expression or an increased release
of CGRP (63).
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Figure 2. Graphical representation of changes in ovarian hor-
mones levels during different stages of the human and rat
reproductive menstrual cycle. Falling estradiol levels are asso-
ciated with high migraine incidence. Redrawn from (4,81): (a)
Human menstrual cycle and (b) Rat estrous cycle.
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An optimization of the previous model was done by
studying a dermatome in the human forehead inner-
vated by the frontal branch of the ophthalmic (V1)
nerve, where the increase in dermal blood ﬂow is pro-
duced by trigeminal nerve activation via topical capsa-
icin application or electrical stimulation of the forehead
skin (64).
Using this new speciﬁc model, a recent study explored
the eﬀects of the menstrual cycle on trigeminal nerve-
induced vasodilatation in healthy reproductive women
with a regular menstrual cycle, postmenopausal women,
and patients with menstrually related migraine (MRM).
Cycle-dependent changes in trigeminovascular reactivity
were observed in healthy women with enhanced
responses around their menstruation (65). Notably,
these ﬁndings are similar to those found with pain per-
ception, sensory and vasomotor responses, where trigem-
inal sensitization was produced after an intradermal
injection of capsaicin in the forehead (66). In contrast,
the physiological absence of ovarian steroid hormones in
postmenopausal women did not induce any trigeminal
variation during all measurements. Surprisingly, in
MRM patients, low estradiol levels were detected
during the luteal phase (days 19–21 of the cycle), while
cyclic dermal blood ﬂow diﬀerences during the menstrual
cycle were also absent. This could be attributed to a dif-
ferential activity of the TRPV1 channel produced by
estrogens (65), as they alter the expression of the
TRPV1 receptor in sensory neurons (67); however, the
precise mechanisms involved were not explored.
Another non-invasive technique commonly used to
study the trigeminal nociceptive system is functional
neuroimaging. Within this context, Maleki et al. (68)
used high-ﬁeld magnetic resonance imaging (MRI) in
male and female migraineurs to determine interictal
alterations in brain structures using a thermal pain
stressor. Female migraineurs had stronger activation
of the spinal trigeminal nucleus compared with male
migraineurs and healthy controls (68). These ﬁndings
were attributed to diﬀerences in sensitivity of the tri-
geminal system due to hormonal processes, but female
participants were studied without assessing the stage of
the menstrual cycle (68).
A further remarkable study recently reported a
female migraine patient who had a high-ﬁeld MRI
every day for 30 days, while standardized trigeminal
nociceptive stimulation was done during the experi-
ment. It was found that the hypothalamus, depending
on the state of the migraine cycle, exhibited an altered
functional coupling with the spinal trigeminal nucleus,
with the greatest functional coupling in the last 24 h
preceding the onset of the migraine attack (69).
Regrettably, the relationship between the stage of the
menstrual cycle and the activation of the trigeminal
nucleus was not reported in this patient. Using MRI
seems a promising tool for detecting cyclic activation of
the trigeminovascular system during the diﬀerent stages
of the menstrual cycle, and to the best of our know-
ledge, these studies have not yet been performed.
Overall, sex-related diﬀerences in the trigeminal noci-
ceptive system are evident. Notwithstanding, further
experimental research will be required to demonstrate
whether the ﬂuctuations of ovarian hormones levels pro-
duce: (i) a direct eﬀect on trigeminally innervated blood
vessels; (ii) a modulation of prejunctional channels that
release CGRP in the dura mater; or (iii) a modulation of
trigeminal central pain pathways (Figure 1).
CGRP receptor antagonism in females
Because of the unquestionable role of CGRP in
migraine pathophysiology, small molecule CGRP
receptor antagonists such as olcegepant and telcage-
pant (gepants) were developed and proved to be eﬀect-
ive in the acute treatment of migraine headaches
(70,71). The safety and eﬃcacy of telcagepant was
evaluated for short-term prevention of perimenstrual
headaches. When taken perimenstrually for seven
days, telcagepant reduced perimenstrual headaches,
but it was associated with transaminase elevations
in a small number of patients (72). Unfortunately,
clinical trials for chronic migraine treatment were
terminated because of pharmacokinetic limitations
(73) and safety concerns related to hepatotoxicity
(74). Notwithstanding the fact that these drugs have
been discontinued due to side-eﬀects, CGRP receptor
antagonism has been proven eﬀective in migraine treat-
ment and, indeed, other small molecule CGRP recep-
tor antagonists are currently under development.
Moreover, at present, there are four monoclonal anti-
bodies (mAb) in clinical development for migraine
prophylaxis (75–78), namely, three humanized mAb
targeting CGRP (galcanezumab, eptinezumab and fre-
manezumab) and one fully human mAb targeting the
CGRP receptor (erenumab). In migraine patients of
both genders, these drugs have shown eﬃcacy, toler-
ability, and few adverse eﬀects (compared to the
gepants) in phase 2 randomized control trials (75–78).
However, the exact site and mechanism of action of
these novel drugs or the long-term side eﬀects have
not been completely elucidated. Until now, there has
only been one randomized double-blind, placebo-con-
trolled study, where prolonged CGRP inhibition on
cardiovascular parameters was studied in 31 healthy
perimenopausal women. Fortunately, no associated
hemodynamic changes were found after chronically
inhibiting the CGRP pathway with fremanezumab
(79), despite the fact that CGRP (receptor) blockade
might theoretically have a larger impact on cardio-
vascular safety in females than in males (80).
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Thus, additional randomized control trials with the
other mAb should conﬁrm this in women in the repro-
ductive age range.
In summary, CGRP (receptor) blockade is an eﬀect-
ive therapeutic option for treating migraine. Clearly, fur-
ther clinical trials will be required to elucidate whether
these novel drugs are safe in individuals with cardiovas-
cular risk factors, if there are any consequences of
chronic CGRP inhibition in young reproductive
women with a normal menstrual cycle, and whether eﬃ-
cacy depends on the phase of the menstrual cycle.
Future considerations and conclusions
Gender diﬀerences are evident in migraine. Animal
research is starting to shift from including only male
animals to also considering female animals in studies,
but there is still much to be done. Consequently,
gender-related diﬀerences in the CGRP system are
emerging. Numerous animal and human studies have
shown that cyclic ﬂuctuations of ovarian hormones
(mainly estrogen) modulate CGRP in the peripheral
and central trigeminovascular system; this is especially
relevant now that novel antibodies directed against
CGRP or its receptor are currently in clinical trials.
Future studies should focus on how ﬂuctuations of
gonadal hormones inﬂuence migraine pathophysiology
in both genders, especially the estrogen-CGRP relation-
ship that seems a key factor in the higher prevalence of
migraine in women. Hopefully, these sex-related diﬀer-
ences may contribute to the development of gender-
speciﬁc therapies.
Article highlights
. Sex hormone receptors are expressed in the diﬀerent components of the trigeminovascular system.
. Fluctuations of estrogen levels modulate CGRP receptor signaling in the trigeminovascular system.
. The estrogen-CGRP relationship seems to be a key factor involved in the higher prevalence of migraine in
women.
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